N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease

Therapeutic Advances in Respiratory Disease

Volumn 6, Issue 3, 2012, Pages 127-135

  Sadowska, Anna M ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

COPD; mucolysis; NAC

Indexed keywords

ACETYLCYSTEINE; DORNASE ALFA; EXPECTORANT AGENT; GLUTATHIONE; MUCIN; MUCOLYTIC AGENT; REACTIVE OXYGEN METABOLITE; THIOL GROUP;

ANGIOGENESIS; APOPTOSIS; CELL GROWTH; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; INFLAMMATION; MUCOLYSIS; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ACETYLCYSTEINE; EXPECTORANTS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MUCINS; MUCUS; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84861903788     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465812437563     Document Type: Article

References (50)

1. Adler K.B. Fischer B.M. Wright D.T. Cohn L.A. Becker S. (1994) Interactions between respiratory epithelial cells and cytokines: relationships to lung inflammation. Ann N Y Acad Sci 725: 128–145.
2. Basbaum C. Lemjabbar H. Longphre M. Li D. Gensch E. McNamara N. (1999) Control of mucin transcription by diverse injury-induced signaling pathways. Am J Respir Crit Care Med 160: S44's48.
3. Bridgeman M.M. Marsden M. Selby C. Morrison D. Macnee W. (1994) Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax 49: 670–675.
4. Davis S.S. Scobie S. Inglis A. (1975) The effect of sulphydryl compounds and cross linking agents on the viscous and viscoelastic properties of mucus. Biorheology 12: 225–232.
5. De Caro L. Ghizzi A. Costa R. Longo A. Ventresca G.P. Lodola E. (1989) Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers. Arzneimittelforschung 39: 382–386.
6. Decramer M. Rutten-Van Molken M. Dekhuijzen P.N. Troosters T. Van Herwaarden C. Pellegrino R. (2005) Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (bronchitis randomized on NAC cost–utility study, broncus): a randomised placebo-controlled trial. Lancet 365: 1552–1560.
7. Deshmukh H.S. Case L.M. Wesselkamper S.C. Borchers M.T. Martin L.D. Shertzer H.G. (2005) Metalloproteinases mediate mucin 5AC expression by epidermal growth factor receptor activation. Am J Respir Crit Care Med 171: 305–314.
8. Dignass A.U. Podolsky D.K. (1993) Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta. Gastroenterology 105: 1323–1332.
9. Enss M.L. Wagner S. Schmidt-Wittig U. Heim H.K. Beil W. Hedrich H.J. (1997) Effects of PGE2 on amount and composition of high molecular weight glycoproteins released by human gastric mucous cells in primary culture. Prostaglandins Leukot Essent Fatty Acids 56: 93–98.
10. Erjefalt J.S. Erjefalt I. Sundler F. Persson C.G. (1995) In vivo restitution of airway epithelium. Cell Tissue Res 281: 305–316.
11. Fischer B.M. Rochelle L.G. Voynow J.A. Akley N.J. Adler K.B. (1999) Tumor necrosis factor-alpha stimulates mucin secretion and cyclic GMP production by guinea pig tracheal epithelial cells in vitro. Am J Respir Cell Mol Biol 20: 413–422.
12. Gerrits C.M. Herings R.M. Leufkens H.G. Lammers J.W. (2003) N-Acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 21: 795–798.
13. Grandjean E.M. Berthet P. Ruffmann R. Leuenberger P. (2000) Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 22: 209–221.
14. Gray T. Coakley R. Hirsh A. Thornton D. Kirkham S. Koo J.S. (2004) Regulation of MUC5AC mucin secretion and airway surface liquid metabolism by IL-1beta in human bronchial epithelia. Am J Physiol Lung Cell Mol Physiol 286: L320–L330.
15. Harada D. Naito S. Hiraoka I. Otagiri M. (2002) In vivo kinetic analysis of covalent binding between N-acetyl-L-cysteine and plasma protein through the formation of mixed disulfide in rats. Pharm Res 19: 615–620.
16. Hewson C.A. Haas J.J. Bartlett N.W. Message S.D. Laza-Stanca V. Kebadze T. (2010) Rhinovirus induces MUC5AC in a human infection model and in vitro via NF-κB and EGFR pathways. Eur Respir J 36: 1425–1435.
17. Innes A.L. Woodruff P.G. Ferrando R.E. Donnelly S. Dolganov G.M. Lazarus S.C. (2006) Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest 130: 1102–1108.
18. Jang M.K. Kim S.H. Lee K.Y. Kim T.B. Moon K.A. Park C.S. (2010) The tyrosine phosphatase, SHP-1, is involved in bronchial mucin production during oxidative stress. Biochem Biophys Res Commun 393: 137–143.
19. Jeffery P.K. (2004) Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 1: 176–183.
20. Jeffery P. Zhu J. (2002) Mucin-producing elements and inflammatory cells. Novartis Found Symp 248: 51–68; discussion 68–75, 277–282.
21. Kasielski M. Nowak D. (2001) Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 95: 448–456.
22. Kim S. Nadel J.A. (2004) Role of neutrophils in mucus hypersecretion in COPD and implications for therapy. Treat Respir Med 3: 147–159.
23. Longphre M. Li D. Gallup M. Drori E. Ordonez C.L. Redman T. (1999) Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells. J Clin Invest 104: 1375–1382.
24. Lu Y. Qin W. Shen T. Dou L. Man Y. Wang S. (2011) The antioxidant N-acetylcysteine promotes atherosclerotic plaque stabilization through suppression of RAGE, MMPs and MF-κB in ApoE-deficient mice. J Atheroscler Thromb 18: 998–1008.
25. Macnee W. Bridgeman M.M. Marsden M. Drost E. Lannan S. Selby C. (1991) The effects of N-acetylcysteine and glutathione on smoke-induced changes in lung phagocytes and epithelial cells. Am J Med 91: 60S–66S.
26. Martin L.D. Rochelle L.G. Fischer B.M. Krunkosky T.M. Adler K.B. (1997) Airway epithelium as an effector of inflammation: molecular regulation of secondary mediators. Eur Respir J 10: 2139–2146.
27. Mata M. Ruiz A. Cerda M. Martinez-Losa M. Cortijo J. Santangelo F. (2003) Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin muc5ac expression in rats. Eur Respir J 22: 900–905.
28. Nadel J.A. (2000) Role of neutrophil elastase in hypersecretion during copd exacerbations, and proposed therapies. Chest 117: 386S–389S.
29. Perez-Vilar J. Mabolo R. McVaugh C.T. Bertozzi C.R. Boucher R.C. (2006) Mucin granule intraluminal organization in living mucous/goblet cells. roles of protein post-translational modifications and secretion. J Biol Chem 281: 4844–4855.
30. Pettersen C.A. Adler K.B. (2002) Airways inflammation and CODP: epithelial–neutrophil interactions. Chest 121: 142S–150S.
31. Prescott E.I. Lange P. Vestbo J. (1996) [Chronic expectoration and risk of death in chronic obstructive lung disease]. Ugeskr Laeger 158: 6456–6460.
32. Prescott L.F. Donovan J.W. Jarvie D.R. Proudfoot A.T. (1989) The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. Eur J Clin Pharmacol 37: 501–506.
33. Rahman I. Macnee W. (2000) Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. Free Radic Biol Med 28: 1405–1420.
34. Rogers D.F. (2001) Mucus hypersecretion in chronic obstructive pulmonary disease. Novartis Found Symp 234: 65–77; discussion 77–83.
35. Rogers D.F. (2007) Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir Care 52: 1134–1146; discussion 1146–1149.
36. Rogers D.F. Turner N.C. Marriott C. Jeffery P.K. (1989) Oral N-acetylcysteine or S-carboxymethylcysteine inhibit cigarette smoke-induced hypersecretion of mucus in rat larynx and trachea in situ. Eur Respir J 2: 955–960.
37. Rubin B.K. (2007) Mucolytics, expectorants, and mucokinetic medications. Respir Care 52: 859–865.
38. Sadowska A.M. Manuel Y.K.B. De Backer W.A. (2007) Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: A Review. Pulm Pharmacol Ther 20: 9–22.
39. Saetta M. Turato G. Baraldo S. Zanin A. Braccioni F. Mapp C.E. (2000) Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med 161: 1016–1021.
40. Santangelo F. (2003) Intracellular thiol concentration modulating inflammatory response: influence on the regulation of cell functions through cysteine prodrug approach. Curr Med Chem 10: 2599–2610.
41. Schweitzer K.S. Hatoum H. Brown M.B. Gupta M. Justice M.J. Beteck B. (2011) Mechanisms of lung endothelial barrier disruption induced by cigarette smoke: role of oxidative stress and ceramides. Am J Physiol Lung Cell Mol Physiol 301: L836–L846.
42. Shao M.X. Nadel J.A. (2005) Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF-alpha-converting enzyme. J Immunol 175: 4009–4016.
43. Sheffner A.L. (1963) The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetyl-L-cysteine. Ann N Y Acad Sci 106: 298–310.
44. Takeyama K. Dabbagh K. Jeong Shim J. Dao-Pick T. Ueki I.F. Nadel J.A. (2000) Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils. J Immunol 164: 1546–1552.
45. Temann U.A. Geba G.P. Rankin J.A. Flavell R.A. (1998) Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med 188: 1307–1320.
46. Temann U.A. Prasad B. Gallup M.W. Basbaum C. Ho S.B. Flavell R.A. (1997) A novel role for murine IL-4 in vivo: induction of MUC5AC gene expression and mucin hypersecretion. Am J Respir Cell Mol Biol 16: 471–478.
47. Van Overveld F.J. Vermeire P.A. De Backer W.A. (2000) Induced sputum of patients with chronic obstructive pulmonary disease (COPD) contains adhesion-promoting, therapy-sensitive factors. Inflamm Res 49: 8–13.
48. Vestbo J. (2002) Epidemiological studies in mucus hypersecretion. Novartis Found Symp 248: 3–12; discussion 12–19, 277–282.
49. Yang J. Li Q. Zhou X.D. Kolosov V.P. Perelman J.M. (2011) Naringenin attenuates mucous hypersecretion by modulating reactive oxygen species production and inhibiting NF-κB activity via EGFR-PI3K-Akt/ERK MAPKinase signaling in human airway epithelial cells. Mol Cell Biochem 351: 29–40.
50. Ziment I. (1986) Acetylcysteine: a drug with an interesting past and a fascinating future. Respiration 50 (Suppl. 1): 26–30.